Nikhil Vasudeva, Medical Oncologist at B.R.A. IRCH AIIMS Delhi and NCI Jhajjar, shared Kohei Shitara’s, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, post on X, adding:
“Does tislelizumab actually make a difference in HERIZON-GEA-01 when median OS looks fairly similar with and without it?
At first glance:
- Zanidatamab + tislelizumab + chemotherapy -> median OS 26.4 mo(HR 0.72,Statistically significant)
- Zanidatamab + chemotherapy -> median OS 24.4 mo(HR 0.80,p=0.056)
The biggest signal is in the durability of benefit where we have a fairly striking separation. The ORR in both Zanidatamab groups was ~70% Tislelizumab does not dramatically change the initial response rate, but may help maintain disease control once a response occurs.
The Kaplan-Meier curves support this
Curve separation shows a ‘tail effect’ rather than a large early shift in median outcomes. Although these groups were not directly compared, the difference at 18 and 24 months is evident. RMST might be a more informative metric.”
Quoting Kohei Shitara’s post:
“Thrilled to share phase 3 HERIZON-GEA-01 in NEJM before ASCO.
Biparatopic anti-HER2 Zanidatamab plus chemo±tislelizumab improved PFS in HER2+ gastric/GEJ cancer; the tislelizumab combo also improved OS. Grateful to all patients and collaborators.”
Title: Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Authors: Kohei Shitara, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer Ajani, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Jun Zhao, Cinta Hierro, Andrew Kiberu, Filip Van Herpe, Yuanyuan Bao, Hanze Zhang, Lin Yang, Vincent Li, Elaina M. Gartner, Ye Chen, Jonathan Grim, Sun Young Rha, Lin Shen
Other articles featuring Nikhil Vasudeva and Kohei Shitara on OncoDaily.